Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV

Single use of genotypic antiretroviral resistance testing (GART) after first failure of highly active antiretroviral therapy (HAART) was reported to be cost effective; its use prior HAART initiation is unknown. Guidelines recommend GART after each treatment failure. We assessed the cost effectivenes...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Antiviral therapy 2004-02, Vol.9 (1), p.27-36
Hauptverfasser:	CORZILLIUS, Michael, MÜHLBERGER, Nikolai, SROCZYNSKI, Gaby, JAEGER, Hans, WASEM, Jürgen, SIEBERT, Uwe
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired Immunodeficiency Syndrome - drug therapy Acquired Immunodeficiency Syndrome - economics Acquired Immunodeficiency Syndrome - mortality Anti-HIV Agents - economics Anti-HIV Agents - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral Therapy, Highly Active - economics Antiviral agents Biological and medical sciences Cost-Benefit Analysis Drug Resistance, Viral - genetics Genotype Germany HIV - drug effects HIV - genetics HIV Infections - drug therapy HIV Infections - economics HIV Infections - mortality Humans Life Expectancy Markov Chains Medical sciences Pharmacology. Drug treatments Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!